Product Description
SK08 live bacterial powder, a viable drug developed using B. fragilis, has been approved by the Chinese Food and Drug Administration and is currently in the clinical trial stage. The drug is registered and classified as a therapeutic biological product. The safety and efficacy of SK08 in patients with irritable bowel syndrome. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683952/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Guangzhou Zhiyi Biological Technology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Diarrhea|Irritable Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20210772 | P2 |
Not yet recruiting |
Diarrhea|Irritable Bowel Syndrome |
None |